What is Coronavirus? Everything You Need to Know About the Dangerous Coronavirus

ultimate guide to Coronavirus and its symptoms, risks, and precautions

The World Health Organization (WHO) has announced a worldwide wellbeing crisis over another coronavirus that has executed in excess of 2,700 individuals overall after a flare-up in the focal Chinese city of Wuhan. Here you will get to know what is Coronavirus? and things you need to know about the dangerous new Coronavirus. More than 80,000 cases of infection have been reported globally, most of them in mainland China.

Although India now has three confirmed cases of the Novel Coronavirus, which has claimed over 400 lives in China so far. The third case is from Kerala’s Kasargod district. The patient is said to be stable. The second case from the state is being monitored in an isolation ward at Alappuzha Medical College. The patient who first tested positive for coronavirus is currently hospitalized in Thrissur Medical College and her condition is stable. Kerala has declared a state of calamity after the three positive.

What Exactly, is the Coronavirus?

what is Coronavirus? and things you need to know about the dangerous new Coronavirus.

According to the WHO, coronaviruses are a family of viruses that cause illnesses ranging from the common cold to more severe diseases such as severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS). The name coronavirus comes from the Latin word corona, meaning crown or halo. Under an electron microscope, the image of the virus looks like a solar corona.

These viruses were originally transmitted between animals and people. SARS, for instance, was transmitted from civet cats to humans while MERS moved to humans from a type of camel. The novel coronavirus, identified by Chinese authorities on January 7 and since named COVID-19, is a new strain that had not been previously identified in humans. Little is known about it, although human-to-human transmission has been confirmed.

Several known viruses are circulating in animals that have not yet infected humans.

From Where The Coronavirus Originated?

Although scientists have pointed to either bats or snakes as the source of the virus.

Severe acute respiratory syndrome virus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are two highly transmissible and pathogenic viruses that emerged in humans at the beginning of the 21st century. Both viruses likely originated in bats, and genetically diverse viruses that are related to SARS-CoV and MERS-CoV were discovered in bats worldwide. In this Review, we summarize the current knowledge on the origin and evolution of these two pathogenic coronaviruses and discuss their receptor usage; we also highlight the diversity and potential of spillover of bat-borne coronaviruses, as evidenced by the recent spillover of swine acute diarrhea syndrome coronavirus (SADS-CoV) to pigs.

Where do these viruses come from?

MERS-CoV and SARS-CoV appear to originate in animals, and the same is likely true of SARS-CoV-2. This makes them zoonoses, diseases that can jump between humans and other animals. MERS-CoV and SARS-CoV were originally bat viruses that spread to an intermediate animal (camel and civet cat, respectively), which then exposed humans to the viruses. Genetic analysis of SARS-CoV-2 sequences shows that their closest genetic relatives appear to be bat coronaviruses, with the role of intermediate species possibly played by the pangolin, an endangered species trafficked in China for its scales and meat. There are four coronaviruses that cause colds in humans — known as H-CoV-229E, CoV-NL63, CoV-OC43, and CoV-HKU1 — and these also seem to have zoonotic origins.

How Does Coronavirus Transfer From Animals to Humans?

what is Coronavirus? and things you need to know about the dangerous new Coronavirus.

Researchers aren’t sure how the novel coronavirus first infected people in China, but the viruses that cause SARS and MERS, which originated in bats, provide clues.

1. Proteins on the outer shell of the virus allow it to latch onto cells in the host’s respiratory tract. The proteins’ shapes are determined by the virus’s genes.

2. To infect new hosts, the virus’s genes undergo mutations that alter its surface proteins, allowing them to latch onto the cells of new species.

Also, Read  The Ultimate Guide To Coronavirus| Symptoms, Risks, and Precautions

3. In the case of SARS, the virus jumped from bats to civet cats before gaining the ability to infect humans. In the case of MERS, camels served as the intermediate host.

4. Coronaviruses can also jump directly to humans, without mutating or passing through an intermediate species. Researchers have found the novel coronavirus likely originated in bats, but haven’t pinpointed the source of transmission to humans.

How Does Coronavirus Transfer From Human to Human?

what is Coronavirus? and things you need to know about the dangerous new Coronavirus.

It is likely spread through a cough, sneeze or another contact with saliva, Chinese officials say. There is no evidence of transmission by aerosol, or through the air. MERS and SARS spread mainly through “respiratory droplets” produced when someone coughs or sneezes. Those two viruses spread mostly through close contact.

Scientists are also investigating whether the new virus may spread in feces, as tests have found it in the digestive tract of some patients.

How Easily Does the New Virus Spread?

Disease-modeling experts have estimated that on average, each infected person has transmitted the virus to about 2.6 others, though the range is between 1.5 and 3.5. Those rates are higher than for some influenza viruses, some are lower than SARS, and they are far lower than measles, in which one infected person can transmit the virus to 12 to 18 other people.

Public-health experts caution that these estimates are preliminary, change over time, and can be lowered by measures to prevent the virus from spreading.

Where did the New Coronavirus come from?

The new virus likely came originally from bats, scientists say. It isn’t known exactly where or how it jumped to humans, though. Viruses from bats often infect another mammal first and then mutate to become more transmissible to humans. One hypothesis is that the intermediary animal for this new virus may be a pangolin, a small mammal sold in wildlife markets, prized for its meat and scales covering its body.

Will the virus Die Down by the Summer?

We don’t know yet. Most respiratory viruses, such as flu viruses, are seasonal. We generally know when the peak of flu season will be and can expect the number of flu cases to drop down as we head toward spring and summer, said Dr. Nancy Messonnier, the director of CDC’s National Center for Immunization and Respiratory Diseases in a news conference on Feb. 12. But for the new virus, “I think it’s premature to assume that,” she said.

Also, Read  List of Drugs Used To Treat Coronavirus| Covid-19 Recent Updates

If this new virus behaves similarly to flu viruses, we may see fewer infections as spring and summer roll around. “But this is a new disease, we haven’t even been through six weeks of it much less a year,” Messonnier said. Though hoping the numbers will go down as warm weather approaches, “the aggressive actions we’re taking are because we don’t think we can count on that.”

Coronavirus Vaccine Updates

  • Scientists around the world are working on potential treatments and vaccines for the new coronavirus disease known as COVID-19.
  • Several companies are working on antiviral drugs, some of which are already in use against other illnesses, to treat people who have COVID-19.
  • Other companies are working on vaccines that could be used as a preventive measure against the disease.

Latest Vaccine Used to Treat Coronavirus

Favilavir, the First Approved Coronavirus Drug in China

The National Medical Products Administration of China has approved the use of Favilavir, an anti-viral drug, as a treatment for coronavirus. The drug has reportedly shown efficacy in treating the disease with minimal side effects in a clinical trial involving 70 patients. The clinical trial is being conducted in Shenzhen, Guangdong province.

Here’s a Look at More COVID-19 Vaccines

Moderna / National Institutes of Health. The company began testing its two-dose messenger RNA (mRNA) vaccine in March in a phase 1 clinical trial, with promising results.

In late July, Moderna began phase 3 clinical trials of the vaccine.


In late August, company officials said preliminary phase 1 trial data showed that the vaccine elicited a promising immune response in 10 people between the ages of 56 and 70 as well as 10 people over the age of 70.

The company announced in late October that it had finished recruiting all 30,000 participants in the phase 3 trial. This included more than 7,000 people over the age of 65 and more than 5,000 younger people with chronic conditions that increase their risk of severe COVID-19.

In early October, company officials announced their vaccine won’t be available for wide distribution until spring 2021. Later in the month, Moderna’s CEO told investors that the trial’s data and safety monitoring board could start analyzing study data in November.

In mid-November, Moderna officials reported that their vaccine had achieved an effective rate of 94 percent in initial phase 3 trial results. Experts said more testing and more information are needed.

On November 30, Moderna officials said they would apply to the FDA for its vaccine to be approved for emergency use. Company executives said the vaccine could be available by December 21 if it receives FDA approval.

Pfizer / BioNTech / Fosun Pharma. Drugmaker Pfizer teamed up German biotech company BioNTech and Chinese drugmaker Fosun Pharma to develop a two-dose mRNA vaccine.

In mid-August, company officials said the vaccine had produced a “robust” response in a phase 1/2 clinical trial.

The company launched a phase 3 trial in late July, with a goal to recruit 30,000 people from the United States, Brazil, Argentina, and Germany. They later announced plans to increase this to 44,000 people. In October, the company said it received approval to enroll children as young as 12 years in the trial — the first American trial to include this age group.

As of late October, the trial had enrolled more than 42,000 people. At the time, the company had not yet conducted an interim analysis of the study data, which puts it behind its original goal of doing so by September. However, the company still expects to have enough data sometime in November to apply for emergency use authorization from the FDA.

On November 9, the company announced that its vaccine had been more than 90 percent effective in clinical trial participants.

A few days later, company officials announced they were applying for an emergency use authorization from the FDA for their vaccine. It was the first regulatory approval in the United States for a COVID-19 vaccine. The officials said the vaccine could be available to high-risk groups as early as mid-December.

On December 8, the FDA released documents that reported the Pfizer vaccine offers some protection after the first dose and nearly full protection after a second dose.

Inovio. When COVID-19 appeared in December, drugmaker Inovio had already been working on a DNA vaccine for MERS, which is caused by another coronavirus. This allowed the company to quickly develop a potential COVID-19 vaccine.

Company officials announced at the end of April that it had enrolled 40 healthy volunteers in its phase 1 trial. In late September, the company announced that its phase 2/3 trial is on hold as it responds to the FDA’s questions about the study.

Sanofi / Translate Bio. Drugmaker Sanofi announced in February that it would work with Translate Bio to develop an mRNA vaccine. Preclinical testing showed that the vaccine could elicit a strong immune response in mice and monkeys. The company expects results from its phase 2 trial in early December. After that, they will start a phase 3 study.

CanSino Biologics. Scientists at this Chinese company are also working on a potential vaccine that uses an adenovirus known as Ad5 to carry coronavirus proteins into cells.

In late July, they reported that participants in a phase 2 trial showed a strong immune response when given the vaccine. However, they noted older adults had a weaker response, suggesting two doses might be needed for that segment of the population.

The Chinese military approved the vaccine in June, allowing the vaccine to be given to its armed forces. In August, the company began phase 3 trials in Pakistan, Saudi Arabia, and Russia.

Gamaleya Research Institute. This Russian institute developed a vaccine that includes two adenoviruses, Ad5 and Ad26.

In August, President Vladimir Putin announced that the country’s regulatory agency had approved the vaccine, even before phase 3 trials had started. Russian officials later said the vaccine had received a “conditional registration certificate.”

Results of a phase 1/2 trial found that the vaccine elicited an immune response with mild side effects. Phase 3 trials are currently underway in Russia, Belarus, United Arab Emirates, and India.

Johnson & Johnson. Drugmaker Johnson & Johnson announced in late July that it had begun a phase 1/2 trial in people after their adenovirus vaccine had shown promising results when used in monkeys.

In late September, the company announced it was starting a phase 3 trial of its one-dose vaccine with 60,000 participants. In mid-October, the company announced it was pausing this trial due to an “unexplained illness” with one of the participants. The company has since received permission to restart the study.

In mid-November, Johnson & Johnson officials said they expected their vaccine to be ready for FDA approval by February.

AstraZeneca / University of Oxford. A phase 1 clinical trial at the University of Oxford began in late April. The vaccine is based on a chimpanzee adenovirus, which shuttles coronavirus proteins into cells.

In August, AstraZeneca began phase 3 trials in Brazil, South Africa, and the United States. These trials were halted in September when a study volunteer developed a rare spinal inflammatory disorder called transverse myelitis. The trials were restarted a week later in Brazil and the United Kingdom. In late October, the FDA authorized the U.S. trial to resume.

In mid-November, company officials said their vaccine had produced a strong immune response in a clinical trial that involved people over the age of 70.

Data released on December 8 indicated that the vaccine was safe but only about 70 percent effective.


Sanofi / GSK / TranslateBio. Drugmaker Sanofi is pursuing two vaccines. The company is working with drugmaker GSK on a vaccine based on proteins from the coronavirus. When combined with another compound, called an adjuvant, the proteins elicit an immune response. They expect results from a phase 2 trial in early December, after which they will begin a phase 3 study.

Sanofi is also working with biotech company Translate Bio to develop an mRNA vaccine. They expect to start clinical trials in December.

Novavax. This company received up to $388 million in funding this spring from the Coalition for Epidemic Preparedness Innovations (CEPI), a group that has funded COVID-19 vaccine development. The vaccine is made by attaching virus proteins to microscopic particles.

In August, Novavax launched a phase 2 trial in South Africa. A month later, the company began a phase 3 trial in the United Kingdom. It plans to start another phase 3 trial in the United States by the end of November.

University of Queensland in Australia / CSL. Researchers at the university developed a vaccine by growing viral proteins in cell cultures. They began preclinical testing stages in early April. The phase 1 trial in people began in early July. A phase 2/3 trial is expected to start late this year.

Wuhan Institute of Biological Products / Sinopharm. Chinese company Sinopharm is testing an inactivated virus vaccine developed by the Wuhan Institute of Biological Products. After a successful phase 1 trial, researchers launched phase 3 trials in the UAE in July and a month later in Peru and Morocco.

Beijing Institute of Biological Products / Sinopharm. Sinopharm is testing a second inactivated virus vaccine developed by Beijing Institute of Biological Products.

Phase 3 trials began in June in the UAE and in September in Argentina. In September, the UAE approved the vaccine for use on healthcare workers even before the results of the phase 3 trials.

Sinovac Biotech. This Chinese company launched phase 3 trials of its inactivated virus vaccine in Brazil in July, Indonesia in August, and Turkey in September. In August, the Chinese government issued emergency approval for the vaccine for use on high-risk groups.

Bharat Biotech / Indian Council of Medical Research / Indian National Institute of Virology. Indian company Bharat announced in late October that it was beginning a phase 3 trial of its inactivated virus vaccine.

Everything You Need To Know About Coronavirus Youtube Video

Conclusion on Dangerous Coronavirus

In this article, we have mentioned some basic information about Coronavirus. The above-mentioned information about Coronavirus is collected from different sources and in our next article we will mention information about precautions, symptoms and all updates about Coronavirus.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top